Innoviva (INVA) Projected to Post Quarterly Earnings on Wednesday

Innoviva (NASDAQ:INVA) will likely be issuing its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to post earnings of $0.5150 per share and revenue of $115.31 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:00 PM ET.

Innoviva Stock Performance

Shares of INVA opened at $21.22 on Monday. The firm’s 50 day moving average is $20.99 and its 200-day moving average is $21.85. The stock has a market capitalization of $1.53 billion, a P/E ratio of 5.18, a P/E/G ratio of 3.06 and a beta of 0.38. The company has a debt-to-equity ratio of 0.21, a current ratio of 16.01 and a quick ratio of 15.18. Innoviva has a 12-month low of $17.77 and a 12-month high of $25.15.

Wall Street Analysts Forecast Growth

INVA has been the subject of a number of research reports. Weiss Ratings cut shares of Innoviva from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, September 24th. Wall Street Zen cut Innoviva from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Oppenheimer started coverage on Innoviva in a research report on Wednesday, September 23rd. They set an “outperform” rating and a $35.00 price objective for the company. Cantor Fitzgerald reduced their price objective on Innoviva from $36.00 to $34.00 and set an “overweight” rating for the company in a research note on Friday, August 7th. Finally, Zacks Research upgraded Innoviva from a “strong sell” rating to a “hold” rating in a report on Monday, August 31st. Four equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, Innoviva currently has an average rating of “Moderate Buy” and a consensus target price of $39.25.

About Innoviva

Innoviva, Inc is a healthcare company focused on developing, commercializing and managing medicines, with an emphasis on respiratory and hospital-based therapies. The company’s business model includes royalty interests in marketed products as well as ownership and investment in companies developing or commercializing innovative treatments.

Innoviva receives royalty revenue from respiratory medicines developed in collaboration with GlaxoSmithKline, including Trelegy Ellipta, Anoro Ellipta and Relvar/Breo Ellipta.